Loading...
Market
Story
Moderna's mRNA Mpox Vaccine Shows Strong Protection in Animal Study, Stock Rises 1.44%
Sep 4, 2024, 03:03 PM
Moderna has reported encouraging results for its mRNA mpox vaccine in a recent animal study. The study, which compared the Moderna vaccine to the Jynneos vaccine in monkeys, found that the mRNA vaccine provided significantly stronger protection. Unvaccinated animals had a maximum of 1,448 lesions, Jynneos-vaccinated animals had a maximum of 607 lesions, while mRNA-immunized animals had a maximum of 54 lesions. These promising results come as mpox outbreaks continue to spread in Africa. A Phase 1/2 human trial for the Moderna mpox vaccine is already underway. Moderna's stock rose by 1.44% following the announcement.
View original story
Similar markets
Successful with no major side effects • 25%
Successful with some side effects • 25%
Unsuccessful • 25%
Inconclusive • 25%
Successful with strong immune response • 25%
Moderate success • 25%
No significant effect • 25%
Trial halted • 25%
Positive • 25%
Negative • 25%
Mixed • 25%
Not published • 25%
Yes • 50%
No • 50%
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
No results announced • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Safety concerns resolved • 25%
Further investigation required • 25%
Vaccine trials permanently halted • 25%
Other outcome • 25%
Successful efficacy • 25%
Partial efficacy • 25%
No efficacy • 25%
Trial discontinued • 25%
Significant improvement in lesion resolution • 25%
No improvement in lesion resolution • 25%
Worsening of lesion resolution • 25%
Trial inconclusive • 25%
Full approval • 25%
Emergency use authorization • 25%
Conditional approval • 25%
No approval • 25%